New Weight‑Loss Compound Boosts Fat Burn Without Cutting Muscle

Scientists at the University of California, Berkeley have identified a compound called TOFA that increases energy expenditure in obese mice. Unlike the popular drug semaglutide, TOFA does not trigger muscle loss or suppress appetite, suggesting a safer pathway for weight management.

How TOFA Works in the Body

TOFA appears to stimulate metabolic pathways that enhance the body’s calorie-burning capacity. In laboratory tests, mice treated with TOFA showed higher rates of energy use, leading to significant fat reduction while preserving lean muscle mass.

Comparison With Semaglutide

Semaglutide, a glucagon‑like peptide‑1 (GLP‑1) agonist, is effective at weight loss but often causes muscle wasting as a side effect. The Berkeley study highlights that TOFA’s mechanism avoids this drawback, making it a potentially more balanced option for patients concerned about muscle preservation.

Implications for Human Treatment

While the findings are promising, TOFA’s safety and efficacy in humans remain untested. Further clinical trials will be necessary to determine appropriate dosing, long‑term effects, and whether the compound can replicate the mouse results in people.

Next Steps in Research

Researchers plan to investigate TOFA’s impact on metabolic health markers, such as insulin sensitivity and lipid profiles, in larger animal models before moving to human studies. The goal is to develop a weight‑loss therapy that maximizes fat loss while minimizing adverse effects.

Source: Fox News

Watch and listen free on JASTORM – Follow radio and video broadcasts free in the JASTORM app with your free account.